多西他赛联合替吉奥治疗复发转移性乳腺癌的临床分析  

Clinical analysis of combining docetaxel and S-1 in treatment of metastatic breast cancer

作　　者：谢家印[1] 向大开[1] 王东[1] 杜佳[1] 邹华[1] 罗维[1] 

机构地区：[1]第三军医大学大坪医院野战外科研究所肿瘤中心,重庆400042

出　　处：《第三军医大学学报》2011年第22期2414-2416,共3页Journal of Third Military Medical University

摘　　要：目的观察和评价国产多西他赛联合替吉奥治疗复发转移性乳腺癌的临床疗效和毒副反应。方法回顾性分析我院自2008年1月至2010后12月经多西他赛联合替吉奥治疗的50例复发转移性乳腺癌患者。结果 50例患者CR 3例,PR 14例,SD 16例,PD 17例,ORR 34.0%,CBR 48.0%。中位生存期为415 d,中位疾病进展时间为163 d。16例早期阶段(化疗≤2个周期)和34例后期阶段(化疗>2个周期)患者其ORR分别为50.0%、26.5%,CBR为68.8%、38.2%,后者相比较两组有统计学意义(P<0.05)。31例曾用过多西他赛联合卡培他滨治疗的患者其ORR、CBR为19.4%、32.3%。毒副反应主要是粒细胞减少,Ⅳ级严重不良反应仅占8.0%。结论多西他赛联合替吉奥治疗复发转移性乳腺癌疗效好,毒副作用低,患者生活质量高,尤其用在早期阶段具有明显优势。Objective To analyze the efficacy and safety of combination of docetaxel and S-1 in the treatment of metastatic breast cancer（MBC）.Methods Clinical data of 50 patients with MBC who had been administered docetaxel and S-1 between January 2008 and December 2010 in our hospital were retrospectively reviewed.Results The patients with complete remission partial remission,stable disease and progressive disease were 3,14,16 and 17 respectively.The overall response rate（ORR）,clinical benefit rate（CBR）,median time to treatment failure and overall survival of the 50 patients were 34.0%,48.0%,163 d and 415 d respectively.Among the 16 patients in the first or the second line chemotherapy and the 34 patients in the third and later line chemotherapy,their ORR were 50.0% and 26.5% respectively,but CBR were 68.8% and 38.2% respectively,with significantly difference in CBR between the 2 groups（P0.05）.For the 31 patients who had been treated with docetaxel and capecitabine,their ORR and CBR were 19.4% and 32.3% respectively.The majority of toxicity were granulopenia.Grade 4 events only accounted for 8%.Conclusion Combining docetaxel and S-1 is well-toleratable and safe for MBC patients,with promising efficiency and maintaining their quality of life.When applied in the early stage of MBC,the agents promise a very effective antitumor effect.

关 键 词：转移性乳腺癌 多西他赛 替吉奥 

分 类 号：R737.9[医药卫生—肿瘤] R730.53[医药卫生—临床医学]